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coBACKGROUND Major disparities between women and men in the diagnosis, management, and outcomes of acute
coronary syndrome are well recognized.
OBJECTIVES The aim of this study was to evaluate the impact of implementing a high-sensitivity cardiac troponin I
assay with sex-speciﬁc diagnostic thresholds for myocardial infarction in women and men with suspected acute coronary
syndrome.
METHODS Consecutive patients with suspected acute coronary syndrome were enrolled in a stepped-wedge, cluster-
randomized controlled trial across 10 hospitals. Myocardial injury was deﬁned as high-sensitivity cardiac troponin I
concentration >99th centile of 16 ng/l in women and 34 ng/l in men. The primary outcome was recurrent myocardial
infarction or cardiovascular death at 1 year.
RESULTS A total of 48,282 patients (47% women) were included. Use of the high-sensitivity cardiac troponin I assay
with sex-speciﬁc thresholds increased myocardial injury in women by 42% and in men by 6%. Following implementation,
women with myocardial injury remained less likely than men to undergo coronary revascularization (15% vs. 34%) and to
receive dual antiplatelet (26% vs. 43%), statin (16% vs. 26%), or other preventive therapies (p < 0.001 for all). The
primary outcome occurred in 18% (369 of 2,072) and 17% (488 of 2,919) of women with myocardial injury before and
after implementation, respectively (adjusted hazard ratio: 1.11; 95% conﬁdence interval: 0.92 to 1.33), compared with
18% (370 of 2,044) and 15% (513 of 3,325) of men (adjusted hazard ratio: 0.85; 95% conﬁdence interval: 0.71 to 1.01).
CONCLUSIONS Use of sex-speciﬁc thresholds identiﬁed 5 times more additional women than men with myocardial
injury. Despite this increase, women received approximately one-half the number of treatments for coronary
artery disease as men, and outcomes were not improved. (High-Sensitivity Troponin in the Evaluation of Patients
With Acute Coronary Syndrome [High-STEACS]; NCT01852123). (J Am Coll Cardiol 2019;74:2032–43)
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AND ACRONYM S
CI = conﬁdence interval
cTnI = contemporary cardiac
troponin I
HR = hazard ratio
hs-cTnI = high-sensitivity
cardiac troponin II mportant disparities exist in the diagnosis, man-agement, and outcomes of acute coronary syn-drome between women and men (1–3). Women
with suspected acute coronary syndrome are less
likely to undergo evidence-based investigations and
treatment, and outcomes following myocardial
infarction are consistently poorer compared with
men (1).
The development of high-sensitivity cardiac
troponin assays has resulted in the identiﬁcation of
important sex differences in the reference range of
cardiac troponin, with the 99th centile in men being
twice that in women (4–6). We have previously
demonstrated that the use of a high-sensitivity assay
with sex-speciﬁc thresholds may double the diagnosis
of myocardial infarction in women and identify
women at risk for future cardiac events (7). This raises
the question as to whether the use of single diag-
nostic thresholds has contributed to inequalities in
the diagnosis, management, and outcomes of women
with acute coronary syndrome.SEE PAGE 2044The recently published fourth universal deﬁnition
of myocardial infarction recommends the use of sex-
speciﬁc thresholds for the diagnosis of myocardial
infarction (2). High-STEACS (High-Sensitivity
Troponin in the Evaluation of Patients With Sus-
pected Acute Coronary Syndrome) was the ﬁrst ran-
domized controlled trial to evaluate the introduction
of a high-sensitivity cardiac troponin I (hs-cTnI) assay
with sex-speciﬁc thresholds into clinical practice (8).
The hs-cTnI assay reclassiﬁed 1 in 6 patients with
myocardial injury, but this was not associated with a
reduction in recurrent myocardial infarction or car-
diovascular death at 1 year. In this pre-speciﬁed sec-
ondary analysis, we evaluated the impact of
implementing sex-speciﬁc diagnostic thresholds on
the use of investigation and treatments for coronary
heart disease and on clinical outcomes in women and
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STUDY DESIGN. High-STEACS was a stepped-
wedge, cluster-randomized controlled trial
that evaluated the implementation of an hs-
cTnI assay in consecutive patients present-
ing with suspected acute coronary syndrome
across 10 secondary and tertiary hospitals in
Scotland (NCT01852123) (Online Table 1). The
study design has been described in detail previously
(8), and the study was conducted with the approval of
the Scotland Research Ethics Committee in accor-
dance with the Declaration of Helsinki. During a
validation phase of at least 6 months, a contemporary
cardiac troponin I (cTnI) assay was used to guide
clinical care. Hospital sites were then randomly allo-
cated to early or late implementation of the hs-cTnI
assay and sex-speciﬁc thresholds. Hospital sites
served as the unit of randomization to avoid the risk
for clinical error due to reporting of different troponin
assays and thresholds simultaneously.
PATIENT POPULATION. All patients presenting to
the emergency department were screened by the
attending clinician for suspected acute coronary
syndrome using an electronic form embedded within
the clinical care pathway. Patients who presented
with suspected acute coronary syndrome and had
paired troponin measurements using the contempo-
rary and trial assay were eligible for inclusion. Pa-
tients who were not resident in Scotland or who had
previously been admitted during the trial period were
excluded. Because the intervention was implemented
at the hospital level, individual patient consent was
not sought. This approach ensured that consecutive
patients presenting with suspected acute coronary
syndrome were included without selection bias.
INTERVENTION. Cardiac troponin testing was per-
formed at presentation and repeated 6 or 12 h after
the onset of symptoms at the discretion of the
attending clinician in accordance with national and-Turing Cardiovascular Data Science Award (BCDSA/
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2034international guidelines in use during enrollment
(9,10). Throughout the duration of the trial, all sites
measured cardiac troponin using both the cTnI and
hs-cTnI assays simultaneously. During the validation
phase, only the results of the cTnI assay were re-
ported to the attending clinician, while during the
implementation phase, only the results of the hs-cTnI
assay were reported.
The cTnI assay (ARCHITECT STAT troponin I
assay; Abbott Laboratories, Abbott Park, Illinois) with
a single diagnostic threshold for women and men
was used to guide clinical decisions during the vali-
dation phase. The interassay coefﬁcient of variation
was <10% at 40 ng/l at 7 sites and 50 ng/l at 3 sites, and
these concentrations were used as the diagnostic
thresholds during the validation phase (11). During the
implementation phase, an hs-cTnI assay (ARCHITECT
STAT high-sensitive troponin I assay; Abbott Labora-
tories) was used to guide clinical decisions, with a
sex-speciﬁc 99th centile diagnostic threshold of
16 ng/l for women and 34 ng/l for men (7).
ADJUDICATION OF THE DIAGNOSIS OF MYOCARDIAL
INFARCTION. Two physicians from our adjudication
panel independently reviewed all clinical informa-
tion in those with hs-cTnI concentrations >99th
centile while blinded to the study phase to classify
patients in accordance with the third universal
deﬁnition of myocardial infarction (12). Any dis-
agreements were resolved by a third physician
(Online Appendix).
OUTCOMES. We used regional and national registries
to ensure complete follow-up of the trial population
(7,13,14). The primary outcome was a composite of
type 1 or type 4b myocardial infarction following the
initial presentation to hospital or cardiovascular
death within 1 year. The primary outcome was inde-
pendently adjudicated by 2 physicians blinded to
study phase, and any disagreements were resolved by
a third physician.
STATISTICAL ANALYSIS. All patients with peak hs-
cTnI above the sex-speciﬁc 99th centile were classi-
ﬁed as having myocardial injury. Patients with
myocardial injury were further stratiﬁed into 2
groups: those already identiﬁed by the contemporary
cTnI assay (cTnI concentrations above the diagnostic
threshold of the contemporary assay) and those
reclassiﬁed by the hs-cTnI assay (cTnI concentrations
below the diagnostic threshold of the contemporary
assay). The primary outcome was compared before
and after implementation of the hs-cTnI assay strat-
iﬁed by sex in those with myocardial injury using a
Cox proportional hazards model. The model adjusted
for hospital site (ﬁtted as a random effect), season,time of presentation from the start date of the trial,
age, sex and study phase as an interaction term, his-
tory of diabetes mellitus, ischemic heart disease or
cerebrovascular disease, hs-cTnI, creatinine concen-
tration, and social deprivation. We used the same
model to compare the primary outcome in women
and men reclassiﬁed by the hs-cTnI assay and in post
hoc analyses (Online Appendix). We performed a post
hoc analysis in women, stratiﬁed by the uniform
99th centile diagnostic threshold (26 ng/l). All
statistical analyses were performed using R version
3.5.1 (R Foundation, Vienna, Austria).
RESULTS
Consecutive patients (n ¼ 48,282) with suspected
acute coronary syndrome were included in this trial,
of whom 22,562 (47%) were women and 25,720 (53%)
were men (Online Figure 1). The majority of patients
reclassiﬁed by the hs-cTnI assay and sex-speciﬁc
thresholds were women (1,470 of 1,771 women [83%]
vs. 301 of 1,771 men [17%]), with the total number of
patients with myocardial injury increasing from 3,521
(16%) to 4,991 (22%) in 22,562 women and from 5,068
(20%) to 5,369 (21%) in 25,720 men.
BASELINE CHARACTERISTICS. Across both study
phases, women with myocardial injury were older
than men (75  14 years vs. 68  15 years), although
they had similar cardiovascular risk factors, pre-
existing medications, and risk for mortality (GRACE
[Global Registry of Acute Coronary Events] score 147
 36 vs. 140  39) (Table 1). Women were as likely as
men to present with chest pain (66% vs. 74%) and to
have evidence of myocardial ischemia on electrocar-
diography (27% vs. 36%). Compared with those
identiﬁed by the cTnI assay, both women and men
reclassiﬁed by the hs-cTnI assay were less likely to
have myocardial ischemia on electrocardiography but
had similar age, presenting symptoms, and cardio-
vascular risk factors (Online Table 2).
DIAGNOSIS OF MYOCARDIAL INFARCTION DURING
INDEX ADMISSION. The adjudication panel was able
to achieve a consensus diagnosis in 9,115 of 10,360
patients (88%) with hs-cTnI concentrations above the
sex-speciﬁc 99th centile (Figure 1). The proportions of
women and men with myocardial injury due to type 1
myocardial infarction were 52% (1,609 of 3,118) and
65% (2,904 of 4,445) in those identiﬁed by the cTnI
assay and 32% (401 of 1,270) and 40% (114 of 282) in
those reclassiﬁed by the hs-cTnI assay (Online
Table 2). Overall, the use of an hs-cTnI assay and
sex-speciﬁc thresholds increased the diagnosis of
type 1 myocardial infarction in women by 25% (from
1,609 of 21,959 [7%] to 2,010 of 21,959 [9%]) and in
TABLE 1 Characteristics of Trial Participants With Myocardial Injury, Stratiﬁed by Sex and Study Phase
Overall
(N ¼ 10,360)
Women Men
Overall
(N ¼ 4,991)
Validation
(n ¼ 2,072)
Implementation
(n ¼ 2,919)
Overall
(N ¼ 5,369)
Validation
(n ¼ 2,044)
Implementation
(n ¼ 3,325)
Age, yrs 71  15 75  14 76  14 74  14 68  15 68  15 67  15
Presenting symptom*
Chest pain 6,449 (70) 2,880 (66) 940 (64) 1,940 (67) 3,569 (74) 1,076 (72) 2,493 (75)
Dyspnea 1,068 (12) 575 (13) 192 (13) 383 (13) 493 (10) 173 (12) 320 (10)
Palpitation 278 (3) 172 (4) 58 (4) 114 (4) 106 (2) 37 (3) 69 (2)
Syncope 686 (7) 388 (9) 153 (10) 235 (8) 298 (6) 109 (7) 189 (6)
Other 730 (8) 374 (9) 128 (9) 246 (8) 356 (7) 102 (7) 254 (8)
Previous medical conditions
Myocardial infarction 1,379 (13) 631 (13) 291 (14) 340 (12) 748 (14) 325 (16) 423 (13)
Ischemic heart disease 3,457 (33) 1,663 (33) 773 (37) 890 (31) 1,794 (33) 758 (37) 1,036 (31)
Cerebrovascular disease 1,034 (10) 573 (12) 265 (13) 308 (11) 461 (9) 190 (9) 271 (8)
Diabetes mellitus 1,478 (14) 664 (13) 282 (14) 382 (13) 814 (15) 329 (16) 485 (15)
Previous revascularization
PCI 938 (9) 355 (7) 148 (7) 207 (7) 583 (11) 229 (11) 354 (11)
CABG 248 (2) 76 (2) 35 (2) 41 (1) 172 (3) 76 (4) 96 (3)
Medications at presentation
Aspirin 3,701 (36) 1,759 (35) 800 (39) 959 (33) 1,942 (36) 809 (40) 1,133 (34)
P2Y12 inhibitor 1,422 (14) 750 (15) 357 (17) 393 (14) 672 (13) 296 (15) 376 (11)
Dual-antiplatelet therapy† 502 (5) 228 (5) 121 (6) 107 (4) 274 (5) 139 (7) 135 (4)
Statin 5,260 (51) 2,499 (50) 1,100 (53) 1,399 (48) 2,761 (51) 1,097 (54) 1,664 (50)
ACE inhibitor or ARB 4,333 (42) 2,059 (41) 876 (42) 1,183 (41) 2,274 (42) 892 (44) 1,382 (42)
Beta-blocker 3,607 (35) 1,809 (36) 794 (38) 1,015 (35) 1,798 (34) 762 (37) 1,036 (31)
Oral anticoagulant agent‡ 1,095 (11) 587 (12) 269 (13) 318 (11) 508 (10) 204 (10) 304 (9)
Loop diuretic agent 2,693 (26) 1,571 (32) 702 (34) 869 (30) 1,122 (21) 491 (24) 631 (19)
Proton-pump inhibitor 4,638 (45) 2,472 (50) 1,084 (52) 1,388 (48) 2,166 (40) 862 (42) 1,304 (39)
Calcium-channel blocker 1,977 (19) 921 (19) 397 (19) 524 (18) 1,056 (19) 412 (20) 644 (19)
Nicorandil 645 (6) 303 (6) 149 (7) 154 (5) 342 (6) 174 (8) 168 (5)
Ivabradine 146 (1) 68 (1) 25 (1) 43 (1) 78 (1) 33 (1) 45 (1)
Spironolactone 450 (4) 201 (4) 82 (4) 119 (4) 249 (4) 113 (5) 136 (4)
Electrocardiographic results§
Normal 2,672 (34) 1,366 (36) 513 (36) 853 (36) 1,306 (32) 479 (34) 827 (30)
Myocardial ischemia 2,510 (32) 1,023 (27) 342 (24) 681 (28) 1,487 (36) 445 (32) 1,042 (38)
ST-segment elevation 998 (13) 329 (9) 90 (6) 239 (10) 669 (16) 174 (12) 495 (18)
ST-segment depression 1,328 (17) 583 (16) 226 (16) 357 (15) 745 (18) 234 (17) 511 (18)
T-wave inversion 1,277 (16) 640 (17) 252 (17) 388 (16) 637 (15) 232 (16) 405 (15)
Physiological parameters§
Heart rate, beats/min 86  26 88  27 88  27 88  26 84  26 85  25 83  26
Systolic blood pressure, mm Hg 139  29 141  30 140  29 141  30 137  28 136  28 137  28
GRACE risk score 143  38 147  36 148  34 147  38 140  39 139  38 140  40
Hematologic and clinical chemistry measurements
Hemoglobin, g/l 131  25 125  24 124  24 126  23 137  25 136  25 137  25
eGFR, ml/min 47  16 46  16 47  16 46  16 49  15 49  16 48  15
Peak hs-cTnI, ng/l 158 (45–1,622) 82 (30–656) 69 (28–464) 93 (32–831) 294 (67–3,006) 216 (57–1,706) 404 (76–4,395)
Serial hs-cTnI, %k 6,983  67 3,230  65 1,298  63 1,932  66 3,753  70 1,411  69 2,342  70
Adjudicated diagnosis¶
Type 1 MI 5,028 (49) 2,010 (46) 748 (44) 1,262 (47) 3,018 (64) 1,059 (62) 1,959 (65)
Type 2 MI 1,260 (12) 700 (16) 275 (16) 425 (16) 560 (12) 187 (11) 373 (12)
Nonischemic myocardial injury 2,810 (27) 1,673 (38) 670 (40) 1,003 (37) 1,137 (24) 448 (22) 689 (21)
Values are mean  SD, n (%), or median (interquartile range). *Presenting symptom was missing in 5,615 patients (12%). †Two medications from aspirin, clopidogrel, prasugrel, or ticagrelor. ‡Includes
warfarin and direct oral anticoagulant agents. §Electrocardiographic and physiological data were available in 1,377 of reclassiﬁed patients (78%) and 6,470 of identiﬁed patients (75%). kDeﬁned as 2 or more
tests within 24 h of presentation. ¶The adjudication panel was able to achieve consensus diagnoses in 9,098 of 10,360 patients (88%) with hs-cTnI concentrations above the sex-speciﬁc 99th centile.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery bypass grafting; eGFR ¼ estimated glomerular ﬁltration rate; GRACE ¼ Global Registry of Acute
Coronary Events; hs-cTnI ¼ high sensitivity cardiac troponin I; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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FIGURE 1 Flow Diagram of Adjudication Process in Women and Men With Suspected Acute Coronary Syndrome
Total number of patients with
suspected acute coronary syndrome
n = 48,282
Unable to adjudicate
diagnosis in 1,245 patients*
• 642 men; 12%
• 603 women; 12%
47,037 patients
Identified with contemporary cardiac troponin assay (n = 7,563)
Following reclassification with high-sensitivity cardiac troponin assay (n = 9,115)
Women
(n = 21,959; 47%)
1,609 (7%)
505 (2%)
1,000 (5%)
2,904 (12%)
515 (2%)
1,014 (4%)
2,010  (9%)
700 (3%)
1,673 (8%)
3,018 (12%)
560 (2%)
1,137 (5%)
Men
(n = 25,078; 53%)
Type 1 Myocardial infarction
Type 2 Myocardial infarction
Non-ischemic myocardial injury
Type 1 Myocardial infarction
Type 2 Myocardial infarction
Non-ischemic myocardial injury
Adjudicated diagnoses are presented for patients with troponin concentration above the contemporary cardiac troponin I assay threshold of
50 ng/l and those with troponin concentration above the sex-speciﬁc 99th centile threshold of 16 ng/l in women and 34 ng/l in men. *Where
there was consensus among the adjudication panel that there was insufﬁcient clinical information to make a deﬁnitive diagnosis, because of
missing admission or discharge letters, we did not attempt to adjudicate the diagnosis (1,245 of 10,360 [12%]). As we had access to all other
information, including medical history, clinical investigations, management, and outcomes, these patients were not excluded from our
primary or secondary analyses.
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25,078 [12%]) (Figure 1). The use of an hs-cTnI assay
and sex-speciﬁc thresholds increased the diagnosis of
type 2 myocardial infarction in women by 39% (from
505 of 21,959 [2%] to 700 of 21,959 [3%]) and in men
by 9% (from 515 of 25,078 [2%] to 560 of 25,078 [2%])
and increased the diagnosis of nonischemic myocar-
dial injury in women by 67% (from 1,000 of 21,959[5%] to 1,673 of 21,959 [8%]) and in men by 12% (from
1,014 of 25,078 [2%] to 1,137 of 25,078 [2%]).
MANAGEMENT OF WOMEN AND MEN DURING INDEX
ADMISSION. Women with myocardial injury pre-
senting in the implementation phase were more likely
than those presenting during the validation phase to
undergo coronary angiography (18% vs. 26%) and
coronary revascularization (10% vs. 15%) (p < 0.001
TABLE 2 Management of Patients With Myocardial Injury During Initial Hospital Admission, Stratiﬁed by Sex and Study Phase
Overall
(N ¼ 10,360)
Women Men
Overall
(N ¼ 4,991)
Validation
(n ¼ 2,072)
Implementation
(n ¼ 2,919) p Value*
Overall
(N ¼ 5,369)
Validation
(n ¼ 2,044)
Implementation
(n ¼ 3,325) p Value*
Duration of stay, h 74 (23–165) 76 (21–186) 71 (8–195) 79 (28–177) <0.001 73 (26–146)† 75 (14–153) 72 (31–142) 0.247
Coronary angiography 3,425 (33) 1,120 (22) 367 (18) 753 (26) <0.001 2,305 (43)† 770 (38) 1,535 (46) <0.001
PCI 2,162 (21) 624 (13) 194 (9) 430 (15) <0.001 1,538 (29)† 472 (23) 1,066 (32) <0.001
CABG 158 (2) 31 (1) 11 (1) 20 (1) 0.617 127 (2)† 54 (3) 73 (2) 0.341
PCI or CABG 2,315 (22) 654 (13) 205 (10) 449 (15) <0.001 1,661 (31)† 524 (26) 1,137 (34) <0.001
New antiplatelet drug 4,094 (40) 1,580 (32) 595 (29) 985 (34) <0.001 2,514 (47)† 877 (43) 1,637 (49) <0.001
New DAPT 3,383 (33) 1,225 (25) 453 (22) 772 (26) <0.001 2,158 (40)† 726 (36) 1,432 (43) <0.001
New statin therapy 2,034 (20) 704 (14) 237 (11) 467 (16) <0.001 1,330 (25)† 455 (22) 875 (26) 0.001
New ACE inhibitor or ARB 1,945 (19) 685 (14) 255 (12) 430 (15) 0.016 1,260 (24)† 450 (22) 810 (24) 0.055
New beta-blocker 2,559 (25) 960 (19) 322 (16) 638 (22) <0.001 1,599 (30)† 571 (28) 1,028 (31) 0.023
New oral anticoagulant agent 643 (6) 313 (6) 119 (6) 194 (7) 0.216 330 (6) 117 (6) 213 (6) 0.346
Values are median (interquartile range) or n (%). *Chi-square and Mann-Whitney U-tests comparing the validation and implementation phases. †p < 0.05 comparing women
and men.
DAPT ¼ dual-antiplatelet therapy; other abbreviations as in Table 1.
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men with myocardial injury, coronary angiography
and revascularization increased from the validation
to implementation phase (38% vs. 46% and 26% vs.
34%, respectively; p < 0.001 for both). However,
across both phases, rates of coronary angiography
and revascularization were lower in women
compared with men (p < 0.001 for both). Likewise,
prescriptions for preventive therapies increased
following implementation in both women and men
but across both phases remained lower in women
(Table 2). These differences in management between
women and men were also observed in patients older
and younger than the median age of 73 years
(Online Figure 2).
Across both phases, women with type 1 myocardial
infarction were less likely than men to undergo cor-
onary angiography (43% vs. 66% during the valida-
tion phase and 53% vs. 73% during the
implementation phase; p < 0.001 for both) and coro-
nary revascularization (26% vs. 48% and 35% vs. 57%,
respectively; p < 0.001 for both) (Online Table 5,
Online Figure 3). They were also less likely than men
to receive prescriptions for secondary prevention
such as dual-antiplatelet therapy (48% vs. 61% during
the validation phase and 54% vs. 67% during the
implementation phase; p < 0.001 for both), statins
(24% vs. 37% and 31% vs. 41%, respectively; p < 0.001
for both), and beta-blockers (26% vs. 42% and 33% vs.
42%, respectively; p < 0.001 for both).
On comparing rates of the primary outcome
between participants receiving different treatments,
we observed heterogeneity between women and
men (Figure 2). Women who received angiotensin-converting enzyme or angiotensin receptor blockers,
statins, and beta-blockers had a similar reduction in
risk for subsequent myocardial infarction or death
from cardiovascular death as men. However, the ef-
ﬁcacy was lower in women compared with men for
coronary revascularization (adjusted odds ratio: 0.90
[95% conﬁdence interval (CI): 0.68 to 1.17] vs. 0.51
[95% CI: 0.41 to 0.63]; p for interaction < 0.001) and
the use of dual-antiplatelet therapy (adjusted odds
ratio: 0.61 [95% CI: 0.49 to 0.76] vs. 0.42 [95% CI: 0.34
to 0.51]; p for interaction ¼ 0.003) (Online Tables 6
and 7). Differences in treatment efﬁcacy between
women and men persisted in a sensitivity analysis
restricted to those with type 1 myocardial infarction
and were more pronounced in younger women
compared with younger men for both revasculariza-
tion and dual-antiplatelet therapy (p for
interaction < 0.001 for both) (Online Tables 8 and 9,
Online Figures 2 and 3).
CLINICAL OUTCOMES OF WOMEN AND MEN. Over-
all, the primary outcome occurred in 5% of all pa-
tients (2,586 of 48,282) across both phases of the trial.
The primary outcome occurred in 18% of women (369
of 2,072) with myocardial injury during the validation
phase and in 17% (488 of 2,919) during the imple-
mentation phase (adjusted hazard ratio [HR]: 1.11;
95% CI: 0.92 to 1.33; p ¼ 0.289) (Figure 3, Online
Table 10). In men with myocardial injury, the pri-
mary outcome occurred in 18% (370 of 2,044) during
the validation phase and in 15% (513 of 3,325) during
the implementation phase (adjusted HR: 0.85;
95% CI: 0.71 to 1.01; p ¼ 0.071; p for phase-sex
interaction ¼ 0.101) (Online Table 11). Primary and
secondary outcomes in those women and men with
FIGURE 2 Patient Management During Index Hospitalization and Adjusted Odds Ratio of Myocardial Infarction or Cardiovascular Death at 1 Year Stratiﬁed by
Treatment Received During Index Hospitalization and Sex
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(Top) Odds ratio of myocardial infarction and cardiovascular death at 1 year in patients receiving each treatment modality compared with those not receiving treatment
for all patients and stratiﬁed by sex. Odds ratios were adjusted for hospital site (ﬁtted as a random effect), season, time of presentation from the start date of the trial,
age, sex and study phase as an interaction term, history of diabetes mellitus, ischemic heart disease or cerebrovascular disease, high sensitivity cardiac troponin I,
creatinine concentration, and social deprivation. (Middle) Treatment commenced during index hospitalization in all patients and stratiﬁed by sex. (Bottom)
Pre-existing treatment prior to index presentation in all patients and stratiﬁed by sex. ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
CI ¼ conﬁdence interval; DAPT ¼ dual-antiplatelet therapy.
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2038type 1 myocardial infarction and reclassiﬁed by
hs-cTnI are reported in Online Tables 12 and 13,
respectively. Across both phases, there were no dif-
ferences in the primary outcome between women and
men already identiﬁed with myocardial injury (17%
[857 of 4,991] vs. 16% [883 of 5,369]; HR: 0.88;
95% CI: 0.76 to 1.02), between women and men
reclassiﬁed by the hs-cTnI assay (13% [195 of 1,470]
vs. 14% [41 of 301]; HR: 0.93; 95% CI: 0.52 to 1.68), andbetween women and men without myocardial injury
(2% [333 of 17,571] vs. 3% [513 of 20,351]; HR: 1.02;
95% CI: 0.82 to 1.27).
STRATIFICATION BY UNIFORM DIAGNOSTIC
THRESHOLD. Women with hs-cTnI concentrations
between the sex-speciﬁc threshold (16 ng/l) and the
uniform threshold (26 ng/l) were of a similar age and
had similar prevalence of pre-existing medical con-
ditions and cardiovascular risk factors as women with
FIGURE 3 Incidence of Myocardial Infarction or Cardiovascular Death at 1 Year in Women and Men, Stratiﬁed by Troponin Concentration and Study Phase
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(Left) Cumulative incidence time-to-event curves for the primary outcome of myocardial infarction or cardiovascular death at 1 year for men admitted during the
validation phase (dashed line) and implementation phase (solid line). Patients are grouped according to whether myocardial injury was present (blue) or absent (gray).
Paired log-rank test results are p ¼ 0.01 for men with myocardial injury and p ¼ 0.06 for men without myocardial injury. (Right) Cumulative incidence time-to-event
curves for the primary outcome of myocardial infarction or cardiovascular death at 1 year for women admitted during the validation phase (dashed line) and
implementation phase (solid line). Patients are grouped according to whether myocardial injury was present (red) or absent (gray). Paired log-rank test results are
p ¼ 0.40 for women with myocardial injury and p ¼ 0.08 for women without myocardial injury.
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2039hs-cTnI concentrations higher than 26 ng/l but were
less likely to receive evidence-based treatment
(Online Tables 14 and 15). Compared with women
with hs-cTnI concentrations higher than 26 ng/l,
women with hs-cTnI concentrations between 16 and
26 ng/l had similar index diagnoses and rates of the
primary outcome at 1 year (13.4% [121 of 901] vs.
13.0% [74 of 569]) (Online Table 16).
DISCUSSION
The implementation of sex-speciﬁc thresholds for
hs-cTnI had several important implications for the
diagnosis, management, and outcomes of women and
men with suspected acute coronary syndrome. First,
it reclassiﬁed 5 times more additional women than
men with myocardial injury. As such, the same pro-
portion of women and men are now identiﬁed ashaving myocardial injury. Second, implementation
was associated with increased rates of coronary
angiography and revascularization, and increases in
the use of secondary preventive therapy in all pa-
tients. Third, despite the identiﬁcation of more
women with myocardial injury following the adop-
tion of sex-speciﬁc thresholds, women admitted
during the implementation phase remained less likely
to be investigated and treated for coronary artery
disease than men. Finally, the rates of subsequent
myocardial infarction or cardiovascular death were
unchanged in both women and men following
implementation of hs-cTnI testing (Central
Illustration).
Despite the latest recommendations from the
fourth universal deﬁnition of myocardial infarction,
the majority of health care systems worldwide use a
single threshold for the diagnosis of myocardial
CENTRAL ILLUSTRATION Implementation of High-Sensitivity Troponin and Sex-Speciﬁc Thresholds
Sex-specific thresholds identified 5-times more
additional women than men with myocardial injury
Despite this, women received fewer treatments
for coronary artery disease than men
And their outcomes were not improved.
Adjusted Hazard Ratio: Women 1.11 (95% CI: 0.92 - 1.33)
Men 0.85 (95% CI: 0.71 - 1.01)
Coronary
revascularization
(35% versus 57%)
Dual anti-platelet
therapy
(54% versus 67%)
Women
Men
Type 1 MI
Type 2 MI
Non-ischemic
myocardial
injury
Lee, K.K. et al. J Am Coll Cardiol. 2019;74(16):2032–43.
Sex-speciﬁc thresholds identiﬁed 5 times more additional women than men with myocardial injury. Despite this, women received fewer treatments for coronary artery
disease than men, and their outcomes were not improved. CI ¼ conﬁdence interval; MI ¼ myocardial infarction.
Lee et al. J A C C V O L . 7 4 , N O . 1 6 , 2 0 1 9
Sex-Speciﬁc Thresholds of hs-cTnI O C T O B E R 2 2 , 2 0 1 9 : 2 0 3 2 – 4 3
2040infarction in women and men (15). The impact of
sex-speciﬁc thresholds on the diagnosis of myocardial
infarction has been evaluated in a number of obser-
vational studies with divergent ﬁndings (7,16–20).
Most of these studies enrolled selected patients with
acute coronary syndrome, of whom the majority were
men. Furthermore, sex-speciﬁc thresholds were not
used to guide clinical care or subsequent investiga-
tion for coronary artery disease. Here, we imple-
mented sex-speciﬁc thresholds into routine clinical
care in a randomized controlled trial and evaluated
their impact in consecutive patients presenting with
suspected acute coronary syndrome. We found that
use of sex-speciﬁc thresholds identiﬁed proportion-
ately more women, such that the overall percentages
of women and men identiﬁed as having myocardial
injury are now similar. This ﬁnding is intuitive, given
that similar proportions of women and men had risk
factors for ischemic heart disease, presented with
chest pain, and had ischemic changes on electrocar-
diography. Implementation of sex-speciﬁc thresholds
signiﬁcantly increased the diagnosis of type 1 and
type 2 myocardial infarction in women but had little
impact in men.Although hs-cTnI testing identiﬁed similar pro-
portions of women and men with myocardial injury,
we continue to observe major differences in their
management. Women remain one-half as likely as
men to receive treatment for acute coronary syn-
drome even after implementation of the hs-cTnI
assay and sex-speciﬁc thresholds. A higher propor-
tion of women had non-ischemic myocardial injury
compared with men, and this might have accounted
for the lower provision of therapies, because these
therapies may not be indicated and there is no evi-
dence from randomized controlled trials to guide
treatment in this group of patients. However, this is
not the only explanation for the disparity in
treatment, as in our subgroup analyses restricted to
those women and men with adjudicated diagnoses of
type 1 myocardial infarction, treatment differences
persisted.
Could differences in the provision and effective-
ness of treatment explain why we did not observe an
improvement in outcomes following the imple-
mentation of hs-cTnI? The primary analysis of the
High-STEACS trial demonstrated no reduction in
subsequent incidence of myocardial infarction or
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2041cardiovascular death at 1 year (8). Here, we report the
primary outcome stratiﬁed by sex. The vast majority
of patients reclassiﬁed by the sex-speciﬁc thresholds
were women, but we did not observe any improve-
ment in their outcomes. There was also no difference
in the primary outcome in men, but as very few men
were reclassiﬁed, we were underpowered for this
subgroup.
A number of observations could explain our ﬁnd-
ings. First and perhaps most important, women were
less likely to receive treatment for acute coronary
syndrome than men. This was a consistent ﬁnding
across both phases of the trial and in those with
adjudicated diagnoses of type 1 myocardial infarc-
tion. The majority of patients reclassiﬁed by the hs-
cTnI assay were women, who were less likely to
receive evidence-based treatments than those
already identiﬁed by the cTnI assay. This suggests
that clinicians may be less willing to investigate or
initiate treatment in patients with modest elevations
in cardiac troponin. Second, we observed lower
treatment efﬁcacy for acute coronary syndrome in
women compared with men. Third, women were
older than men at presentation and more likely to
die of noncardiovascular causes. It is possible that
the opportunity to modify risk in this group of pa-
tients is more limited. However, it is unlikely that
the lower provision and efﬁcacy of treatment in
women could be attributed to their older age at
presentation alone. In a post hoc analysis, we
observed that women younger than the median age
were less likely to receive treatment than men of
the same age. Furthermore, the observed differ-
ences in treatment efﬁcacy between women and
men were restricted to these younger women. It is
plausible that the discordance in treatment provi-
sion and efﬁcacy was due to differences in the
pathophysiology of acute coronary syndromes be-
tween women and men. In observational studies,
women are more likely than men to have plaque
erosions and coronary microembolization (21),
spontaneous coronary artery dissections (22), and
coronary microvascular dysfunction (23), and
women are consistently underrepresented in clinical
trials of cardiovascular therapies (24–26). Women
may also have been subjected to clinician bias in
the use of diagnostic tests or provision of therapies
(27) or have had a disproportionate burden of psy-
chosocial risk factors, such as depression or a lack
of social support, which can inﬂuence subsequent
cardiovascular risk (28).
Should international guidelines recommend the
use of sex-speciﬁc thresholds for the diagnosis of
myocardial infarction? Although we did not directlycompare a uniform 99th centile threshold against the
sex-speciﬁc threshold in this trial, our study does
provide some helpful insights into the use of sex-
speciﬁc thresholds. First, use of sex-speciﬁc thresh-
olds identiﬁes similar proportions of women and men
presenting with suspected acute coronary syndrome
with myocardial injury. Second, women and men
reclassiﬁed by the high-sensitivity assay with sex-
speciﬁc thresholds were at similar risk for subse-
quent myocardial infarction or cardiovascular death.
Therefore, use of a lower 99th centile in women
appropriately identiﬁed a group of women who were
at risk for cardiovascular events. Conversely, women
and men with hs-cTnI concentrations below their
respective sex-speciﬁc diagnostic thresholds had
similar rates of cardiovascular events, suggesting that
the use of a higher 99th centile for men did not
inappropriately exclude myocardial injury in those
who may have beneﬁted from being identiﬁed and
treated.
STUDY LIMITATIONS. First, it is possible that our
adjudication panel may have underdiagnosed type 1
myocardial infarction in women, as the rates of cor-
onary angiography were one-half those of men. We
must acknowledge that some misclassiﬁcation may
have occurred.
Second, our estimates of treatment efﬁcacy are
subject to confounding by indication. Despite optimal
adjustment, patients selected for treatment are likely
to differ substantially from those who did not receive
treatment, and we are unable to adjust for this re-
sidual confounding.
Third, the impact of adopting sex-speciﬁc thresh-
olds will differ at hospitals that use lower uniform
thresholds for cardiac troponin, as fewer women
would be reclassiﬁed following implementation of hs-
cTnI into practice.
Fourth, we have implemented sex-speciﬁc 99th
centile thresholds using a high-sensitivity troponin I
assay in our trial, but there are many other high-
sensitivity assays in clinical use worldwide. All
high-sensitivity cardiac troponin assays have
demonstrated differences in the normal reference
range between women and men, suggesting that this
approach should be recommended for all assays (6).
However, the impact of implementing sex-speciﬁc
diagnostic thresholds will differ for those assays for
which the difference between women and men is
modest.
Fifth, our study population consists of patients
who received troponin testing for suspected acute
coronary syndrome in Scotland. We acknowledge that
troponin testing may be performed for other reasons
and varies across different health care systems
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: A sex-speciﬁc threshold
level of high-sensitivity cardiac troponin identiﬁes a
higher proportion of women with myocardial injury
and infarction but may not improve clinical
outcomes when there are disparities in treatment
implementation or efﬁcacy.
TRANSLATIONAL OUTLOOK: Future studies
should focus on improving access to angiographic
evaluation and therapeutic interventions for women
with acute coronary syndromes.
Lee et al. J A C C V O L . 7 4 , N O . 1 6 , 2 0 1 9
Sex-Speciﬁc Thresholds of hs-cTnI O C T O B E R 2 2 , 2 0 1 9 : 2 0 3 2 – 4 3
2042(29,30). The impact of implementing high-sensitivity
cardiac troponin testing is likely to differ when
used in a less selected patient population and
when introduced at hospitals that have used either
higher or lower cardiac troponin thresholds than used
here.
Finally, we did not directly compare whether the
use of sex-speciﬁc thresholds was superior to a uni-
form threshold using a hs-cTnI assay. This question is
being evaluated in a prospective cluster randomized
controlled trial (CODE-MI [Hs-cTn—Optimizing the
Diagnosis of Acute Myocardial Infarction/Injury in
Women] trial; NCT03819894) that will include a
health economic analysis to determine whether
adopting sex-speciﬁc thresholds and identifying
more women at risk is cost effective.
CONCLUSIONS
We report that use of a hs-cTnI assay with sex-
speciﬁc thresholds identiﬁed 5 times as many addi-
tional women with myocardial injury than men, such
that the proportion of women and men with
myocardial injury is now equivalent. Despite this
increase, women remain less likely than men to
receive treatment for myocardial infarction, and the
rates of subsequent myocardial infarction or cardio-
vascular death were not substantially reduced in
either women or men following the implementationof high-sensitivity troponin testing into clinical
practice.
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